Insulin degludec/Liraglutide(Lianbang Biotech)

德谷胰岛素/利拉鲁肽（联邦生物科技）

Report date: 2024/07/23 20:00:08

Base Information

Drug NameInsulin degludec/Liraglutide(Lianbang Biotech)
Drug Alias Nameinsulinum degludecum/liraglutidum地谷胰岛素/利拉鲁肽GLP-1 and basal insulin combination地谷胰岛素/利拉糖肽insulina degludec/liraglutida +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsInsulin receptor agonists
TargetsGlucagon-like peptide 1 receptorInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLianbang Biotechnology (Zhuhai Hengqin) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai Federation Biomedicine Co LtdLianbang Biotechnology (Zhuhai Hengqin) Co LtdZhuhai United Laboratories Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A